SG10201610590UA - Anti-egfr antibodies and uses thereof - Google Patents

Anti-egfr antibodies and uses thereof

Info

Publication number: SG10201610590UA
Authority: SG; Singapore
Prior art keywords: egfr antibodies; egfr; antibodies
Prior art date: 2012-06-25

Application number

SG10201610590UA

Other languages

English (en)

Inventor

Christopher Daly

Gavin Thurston

Nicholas J Padadopoulos

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-25

Filing date

2013-06-25

Publication date

2017-02-27

2013-06-25 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2017-02-27 Publication of SG10201610590UA publication Critical patent/SG10201610590UA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SG10201610590UA 2012-06-25 2013-06-25 Anti-egfr antibodies and uses thereof SG10201610590UA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261663984P	2012-06-25	2012-06-25
US201361821000P	2013-05-08	2013-05-08

Publications (1)

Publication Number	Publication Date
SG10201610590UA true SG10201610590UA (en)	2017-02-27

Family

ID=48782632

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG11201407163XA SG11201407163XA (en)	2012-06-25	2013-06-25	Anti-egfr antibodies and uses thereof
SG10201610590UA SG10201610590UA (en)	2012-06-25	2013-06-25	Anti-egfr antibodies and uses thereof
SG10201804151QA SG10201804151QA (en)	2012-06-25	2013-06-25	Anti-egfr antibodies and uses thereof

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201407163XA SG11201407163XA (en)	2012-06-25	2013-06-25	Anti-egfr antibodies and uses thereof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201804151QA SG10201804151QA (en)	2012-06-25	2013-06-25	Anti-egfr antibodies and uses thereof

Country Status (24)

Country	Link
US (3)	US9132192B2 (ru)
EP (1)	EP2864357B1 (ru)
JP (1)	JP6486268B2 (ru)
KR (1)	KR20150023387A (ru)
CN (1)	CN104411722B (ru)
AR (1)	AR091545A1 (ru)
AU (2)	AU2013280610B2 (ru)
BR (1)	BR112014029099A2 (ru)
CA (1)	CA2876697C (ru)
CL (1)	CL2014003465A1 (ru)
CO (1)	CO7160093A2 (ru)
EA (1)	EA030421B1 (ru)
ES (1)	ES2816645T3 (ru)
HK (1)	HK1206040A1 (ru)
IL (1)	IL235392B (ru)
MX (2)	MX356329B (ru)
MY (2)	MY164604A (ru)
NZ (1)	NZ701633A (ru)
PH (1)	PH12014502437A1 (ru)
SG (3)	SG11201407163XA (ru)
TW (2)	TW201843172A (ru)
UY (1)	UY34876A (ru)
WO (1)	WO2014004427A2 (ru)
ZA (1)	ZA201407927B (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9273143B2 (en) *	2011-09-30	2016-03-01	Regeneron Pharmaceuticals, Inc.	Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
CN103917562B (zh)	2011-09-30	2016-07-06	瑞泽恩制药公司	抗-ErbB3抗体及其用途
EP2970491A4 (en) *	2013-03-15	2016-11-23	Alper Biotech Llc	MONOCLONAL ANTIBODIES AGAINST EGFR AND USES THEREOF
EP3786186A1 (en)	2014-02-28	2021-03-03	Merus N.V.	Antibodies that bind egfr and erbb3
EP3143042B1 (en) *	2014-05-16	2020-06-10	Ablynx N.V.	Immunoglobulin variable domains
TW202440903A (zh)	2015-08-04	2024-10-16	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法（一）
CN105017424B (zh) *	2015-08-31	2021-02-09	北京泱深生物信息技术有限公司	一种egfr抗体可变区及其应用
KR20180100305A (ko)	2015-10-23	2018-09-10	메뤼스 엔.페.	암 성장을 억제하는 결합 분자
CA3007644A1 (en)	2015-12-11	2017-06-15	Regeneron Pharmaceuticals, Inc.	Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
WO2018039499A1 (en)	2016-08-24	2018-03-01	Regeneron Pharmaceuticals, Inc.	Host cell protein modification
US11780925B2 (en)	2017-03-31	2023-10-10	Merus N.V.	ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US12195551B2 (en)	2017-05-17	2025-01-14	Merus N.V.	Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
CN110914293B (zh)	2017-07-06	2024-08-13	里珍纳龙药品有限公司	用于制备糖蛋白的细胞培养工艺
JP2020530028A (ja) *	2017-08-09	2020-10-15	メルスナムローゼフェンノートシャップ	ＥＧＦＲ及びｃＭＥＴに結合する抗体
CN109912716B (zh) *	2017-12-13	2022-08-23	凯惠科技发展(上海)有限公司	一种egfr抗体及其制备方法和应用
MX2020006639A (es)	2017-12-22	2020-09-14	Regeneron Pharma	Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
SG11202005235WA (en)	2018-01-31	2020-07-29	Regeneron Pharma	System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh)	2018-02-02	2023-03-16	美商再生元醫藥公司	用於表徵蛋白質二聚合之系統及方法
BR112020013426A2 (pt)	2018-02-28	2020-12-01	Regeneron Pharmaceuticals, Inc.	métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células
CN111801351A (zh) *	2018-03-14	2020-10-20	豪夫迈·罗氏有限公司	抗体亲和力成熟的方法
US12253490B2 (en)	2018-03-19	2025-03-18	Regeneron Pharmaceuticals, Inc.	Microchip capillary electrophoresis assays and reagents
EP4317959A3 (en)	2018-03-19	2024-03-27	Regeneron Pharmaceuticals, Inc.	Microchip capillary electrophoresis assays and reagents
US12259355B2 (en)	2018-03-19	2025-03-25	Regeneron Pharmaceuticals, Inc.	Microchip capillary electrophoresis assays and reagents
TW202016125A (zh)	2018-05-10	2020-05-01	美商再生元醫藥公司	用於定量及調節蛋白質黏度之系統與方法
CN108680746A (zh) *	2018-06-05	2018-10-19	中国科学院合肥物质科学研究院	一种控制肺癌细胞活力的分子靶标及其应用
SG11202011970TA (en)	2018-08-27	2020-12-30	Regeneron Pharma	Use of raman spectroscopy in downstream purification
SG11202011969WA (en)	2018-08-30	2020-12-30	Regeneron Pharma	Methods for characterizing protein complexes
AU2019340366B2 (en)	2018-09-10	2025-01-02	Mirati Therapeutics, Inc.	Combination therapies
CA3116735A1 (en)	2019-01-16	2020-07-23	Regeneron Pharmaceuticals, Inc.	Methods for characterizing disulfide bonds
JP7659501B2 (ja)	2019-03-22	2025-04-09	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	ＥＧＦＲｘＣＤ２８多特異性抗体
CA3135004A1 (en)	2019-05-13	2020-11-19	Regeneron Pharmaceuticals, Inc.	Improved competitive ligand binding assays
EP4005593A4 (en) *	2019-07-24	2023-08-16	Sinocelltech Ltd.	MULTIVARIABLE DOSING METHOD FOR USE IN THE TREATMENT OF HIGH EGFR EXPRESSION CANCER
IL317159A (en)	2019-09-24	2025-01-01	Regeneron Pharma	Systems and methods for use in chromatography and regeneration
EP4065086A1 (en)	2019-11-25	2022-10-05	Regeneron Pharmaceuticals, Inc.	Sustained release formulations using non-aqueous emulsions
AU2021209866B2 (en)	2020-01-21	2023-07-06	Regeneron Pharmaceuticals, Inc.	Deglycosylation methods for electrophoresis of glycosylated proteins
SG11202110145SA (en)	2020-02-26	2021-10-28	Vir Biotechnology Inc	Antibodies against sars-cov-2 and methods of using the same
KR20230058094A (ko)	2020-08-31	2023-05-02	리제너론 파아마슈티컬스, 인크.	세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
JP2023551446A (ja)	2020-11-25	2023-12-08	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	非水膜乳化を使用した持続放出製剤
IL303675A (en)	2020-12-17	2023-08-01	Regeneron Pharma	Fabrication of protein-encapsulating microgels
CN116761880A (zh)	2021-01-20	2023-09-15	瑞泽恩制药公司	改进细胞培养物中的蛋白质滴度的方法
WO2022187323A1 (en)	2021-03-03	2022-09-09	Regeneron Pharmaceuticals, Inc.	Systems and methods for quantifying and modifying protein viscosity
IL305731A (en)	2021-03-26	2023-11-01	Regeneron Pharma	Methods and systems for developing mixing protocols
US20230027739A1 (en)	2021-05-10	2023-01-26	Entrada Therapeutics, Inc.	Antigen-binding and antigen degradation constructs
TW202314240A (zh)	2021-06-01	2023-04-01	美商再生元醫藥公司	微晶片毛細管電泳分析及試劑
US20230077710A1 (en)	2021-09-08	2023-03-16	Regeneron Pharmaceuticals, Inc.	HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CA3232463A1 (en)	2021-09-20	2023-03-23	Philip Mellors	Methods of controlling antibody heterogeneity
CA3230984A1 (en)	2021-10-07	2023-04-13	Ross BROWNE	Systems and methods of ph modeling and control
WO2023059803A1 (en)	2021-10-07	2023-04-13	Regeneron Pharmaceuticals, Inc.	Ph meter calibration and correction
EP4423018A1 (en)	2021-10-26	2024-09-04	Regeneron Pharmaceuticals, Inc.	Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
CN116333119B (zh) *	2021-12-16	2024-02-23	徕特康(苏州)生物制药有限公司	抗表皮生长因子受体抗体及其制备方法和用途
AU2023233590A1 (en)	2022-03-18	2024-10-17	Regeneron Pharmaceuticals, Inc.	Methods and systems for analyzing polypeptide variants
WO2024015418A1 (en)	2022-07-13	2024-01-18	Regeneron Pharmaceuticals, Inc.	Mild acid immunoassays for detection of analytes
CN120344265A (zh)	2022-10-03	2025-07-18	里珍纳龙药品有限公司	单独使用双特异性EGFR x CD28抗体或其与抗PD-1抗体组合使用治疗癌症的方法
WO2024097660A2 (en) *	2022-11-01	2024-05-10	Providence Health & Services - Oregon	Monoclonal antibodies specific for fas ligand and uses thereof
US20240198253A1 (en)	2022-12-16	2024-06-20	Regeneron Pharmaceuticals, Inc.	Methods and systems for assessing chromatographic column integrity
TW202445135A (zh)	2023-01-25	2024-11-16	美商再生元醫藥公司	液態蛋白質組成物穩定性之建模方法
TW202445126A (zh)	2023-01-25	2024-11-16	美商再生元醫藥公司	基於質譜法之體內共表現抗體之表徵
WO2024163708A1 (en)	2023-02-01	2024-08-08	Regeneron Pharmaceuticals, Inc.	Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
WO2024178213A2 (en)	2023-02-22	2024-08-29	Regeneron Pharmaceuticals, Inc.	System suitability parameters and column aging
US20240366471A1 (en)	2023-05-01	2024-11-07	Regeneron Pharmaceuticals, Inc.	Multidose antibody drug products using phenol or benzyl alcohol
US20250043017A1 (en)	2023-07-10	2025-02-06	Regeneron Pharmaceuticals, Inc.	BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF
WO2025014913A1 (en)	2023-07-10	2025-01-16	Regeneron Pharmaceuticals, Inc.	Bispecific pd-l1xcd28 antibodies and methods of use thereof
WO2025054406A1 (en)	2023-09-08	2025-03-13	Regeneron Pharmaceuticals, Inc.	Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en)	2023-09-18	2025-03-20	Regeneron Pharmaceuticals, Inc.	Methods and systems for developing chromatography protocols
WO2025072597A2 (en)	2023-09-29	2025-04-03	Regeneron Pharmaceuticals, Inc.	Lyophilization using controlled nucleation
WO2025085594A1 (en)	2023-10-18	2025-04-24	Regeneron Pharmaceuticals, Inc.	Rapid purification of monoclonal antibody from in-process upstream cell culture material
CN117430707B (zh) *	2023-10-25	2024-04-19	重庆天科雅生物科技有限公司	一种cik细胞的制备方法及其在治疗癌症中的用途
US20250145662A1 (en)	2023-11-02	2025-05-08	Regeneron Pharmaceuticals, Inc.	Methods for reducing lipase activity using stress

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4943533A (en)	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
LU91067I2 (fr)	1991-06-14	2004-04-02	Genentech Inc	Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5844093A (en)	1994-03-17	1998-12-01	Merck Patent Gesellschaft Mit Beschrankter Haftung	Anti-EGFR single-chain Fvs and anti-EGFR antibodies
US7060808B1 (en)	1995-06-07	2006-06-13	Imclone Systems Incorporated	Humanized anti-EGF receptor monoclonal antibody
US20020173629A1 (en)	1997-05-05	2002-11-21	Aya Jakobovits	Human monoclonal antibodies to epidermal growth factor receptor
US7087411B2 (en)	1999-06-08	2006-08-08	Regeneron Pharmaceuticals, Inc.	Fusion protein capable of binding VEGF
US7638598B2 (en) *	2001-04-06	2009-12-29	The Trustees Of The University Of Pennsylvania	ErbB interface peptidomimetics and methods of use thereof
IL159225A0 (en)	2001-06-13	2004-06-01	Genmab As	Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7595378B2 (en)	2001-06-13	2009-09-29	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2003012072A2 (en) *	2001-08-03	2003-02-13	The Trustees Of The University Of Pennsylvania	Monoclonal antibodies to activated erbb family members and methods of use thereof
MXPA05000403A (es)	2002-07-15	2005-07-22	Genentech Inc	Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
US8323987B2 (en) *	2004-02-17	2012-12-04	The University Of North Carolina At Chapel Hill	Modulation of epidermal growth factor heterodimer activity
WO2005103081A2 (en)	2004-04-20	2005-11-03	Genmab A/S	Human monoclonal antibodies against cd20
AU2006301426A1 (en) *	2005-10-11	2007-04-19	Ablynx N.V.	NanobodiesTM and polypeptides against EGFR and IGF-IR
JP2009515878A (ja) *	2005-11-12	2009-04-16	イーライリリーアンドカンパニー	抗ｅｇｆｒ抗体
US7498142B2 (en)	2006-01-31	2009-03-03	Yeda Research And Development Co., Ltd.	Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
ES2377579T3 (es)	2006-06-02	2012-03-29	Regeneron Pharmaceuticals, Inc.	Anticuerpos de alta afinidad contra el receptor de IL-6 humano
NO347649B1 (no)	2006-12-14	2024-02-12	Regeneron Pharma	Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
IL274393B (en) *	2008-03-18	2022-09-01	Genentech Inc	Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
TWI496582B (zh) *	2008-11-24	2015-08-21	必治妥美雅史谷比公司	雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
TWI461211B (zh) *	2009-03-20	2014-11-21	Genentech Inc	抗－ｈｅｒ抗體
CA2757426A1 (en) *	2009-04-07	2010-10-14	Roche Glycart Ag	Bispecific anti-erbb-2/anti-c-met antibodies
JO3182B1 (ar)	2009-07-29	2018-03-08	Regeneron Pharma	مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011156617A2 (en) *	2010-06-09	2011-12-15	Aveo Pharmaceuticals, Inc.	Anti-egfr antibodies

2013
- 2013-06-20 TW TW107129255A patent/TW201843172A/zh unknown
- 2013-06-20 TW TW102121841A patent/TWI641619B/zh not_active IP Right Cessation
- 2013-06-25 MY MYPI2014003097A patent/MY164604A/en unknown
- 2013-06-25 US US13/925,923 patent/US9132192B2/en active Active
- 2013-06-25 AR ARP130102231 patent/AR091545A1/es unknown
- 2013-06-25 WO PCT/US2013/047476 patent/WO2014004427A2/en active Application Filing
- 2013-06-25 NZ NZ701633A patent/NZ701633A/en not_active IP Right Cessation
- 2013-06-25 HK HK15106655.6A patent/HK1206040A1/xx unknown
- 2013-06-25 MX MX2014014361A patent/MX356329B/es active IP Right Grant
- 2013-06-25 EP EP13735519.4A patent/EP2864357B1/en active Active
- 2013-06-25 KR KR20147035064A patent/KR20150023387A/ko not_active Ceased
- 2013-06-25 CA CA2876697A patent/CA2876697C/en active Active
- 2013-06-25 ES ES13735519T patent/ES2816645T3/es active Active
- 2013-06-25 EA EA201590085A patent/EA030421B1/ru not_active IP Right Cessation
- 2013-06-25 AU AU2013280610A patent/AU2013280610B2/en active Active
- 2013-06-25 BR BR112014029099A patent/BR112014029099A2/pt not_active Application Discontinuation
- 2013-06-25 MY MYPI2017704291A patent/MY181086A/en unknown
- 2013-06-25 CN CN201380033859.6A patent/CN104411722B/zh not_active Expired - Fee Related
- 2013-06-25 JP JP2015518639A patent/JP6486268B2/ja active Active
- 2013-06-25 SG SG11201407163XA patent/SG11201407163XA/en unknown
- 2013-06-25 UY UY34876A patent/UY34876A/es unknown
- 2013-06-25 SG SG10201610590UA patent/SG10201610590UA/en unknown
- 2013-06-25 SG SG10201804151QA patent/SG10201804151QA/en unknown
- 2013-06-25 MX MX2018006118A patent/MX374463B/es unknown
2014
- 2014-10-29 IL IL235392A patent/IL235392B/en active IP Right Grant
- 2014-10-30 ZA ZA2014/07927A patent/ZA201407927B/en unknown
- 2014-10-30 PH PH12014502437A patent/PH12014502437A1/en unknown
- 2014-12-19 CL CL2014003465A patent/CL2014003465A1/es unknown
- 2014-12-24 CO CO14283133A patent/CO7160093A2/es unknown
2015
- 2015-08-06 US US14/820,324 patent/US9789184B2/en active Active
2017
- 2017-09-11 US US15/700,665 patent/US20180036405A1/en not_active Abandoned
2018
- 2018-07-05 AU AU2018204895A patent/AU2018204895A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TW201843172A (zh)	2018-12-16
US20180036405A1 (en)	2018-02-08
EP2864357A2 (en)	2015-04-29
WO2014004427A8 (en)	2014-12-18
MX374463B (es)	2025-03-06
PH12014502437B1 (en)	2015-01-12
BR112014029099A2 (pt)	2017-07-18
ZA201407927B (en)	2015-11-25
CN104411722A (zh)	2015-03-11
US9789184B2 (en)	2017-10-17
HK1206040A1 (en)	2015-12-31
WO2014004427A2 (en)	2014-01-03
US9132192B2 (en)	2015-09-15
MX2014014361A (es)	2015-02-05
EA030421B1 (ru)	2018-08-31
MY181086A (en)	2020-12-17
PH12014502437A1 (en)	2015-01-12
SG10201804151QA (en)	2018-07-30
JP2015521629A (ja)	2015-07-30
CL2014003465A1 (es)	2015-02-27
NZ701633A (en)	2017-08-25
EP2864357B1 (en)	2020-07-01
AU2013280610B2 (en)	2018-04-26
TWI641619B (zh)	2018-11-21
CA2876697A1 (en)	2014-01-03
WO2014004427A3 (en)	2014-03-27
US20130344093A1 (en)	2013-12-26
CN104411722B (zh)	2017-11-17
JP6486268B2 (ja)	2019-03-20
IL235392B (en)	2019-02-28
TW201402610A (zh)	2014-01-16
SG11201407163XA (en)	2014-11-27
EA201590085A1 (ru)	2015-04-30
AU2013280610A1 (en)	2014-11-20
CA2876697C (en)	2021-07-13
CO7160093A2 (es)	2015-01-15
MY164604A (en)	2018-01-30
ES2816645T3 (es)	2021-04-05
KR20150023387A (ko)	2015-03-05
MX356329B (es)	2018-05-24
UY34876A (es)	2013-12-31
US20150337043A1 (en)	2015-11-26
AR091545A1 (es)	2015-02-11
AU2018204895A1 (en)	2018-07-26

Publication	Publication Date	Title
IL281250A (en)	2021-04-29	Anti-PHF-tau antibodies and uses thereof
IL272831A (en)	2020-04-30	Meditops and antibodies bind meditops and their use
ZA201407927B (en)	2015-11-25	Anti-egfr antibodies and uses thereof
ZA201500457B (en)	2021-07-28	Anti-kit antibodies and uses thereof
ZA201501858B (en)	2016-11-30	Anti-mcam antibodies and associated methods of use
IL254416A0 (en)	2017-11-30	Anti-asic1 antibodies and their uses
IL232399A0 (en)	2014-06-30	Anti-2fgfr antibodies and their use
IL229612A0 (en)	2014-01-30	Antibodies against 3angptl and their uses
EP2756094A4 (en)	2015-05-06	ANTI-B7-H4 ANTIBODIES AND USES THEREOF
PL2831117T3 (pl)	2018-03-30	Przeciwciała anty-TLR4 i ich zastosowania
ZA201405554B (en)	2015-12-23	Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
GB201208372D0 (en)	2012-06-27	Antibodies and uses thereof